Sarcoidosis and Obstructive Sleep Apnoea: An Intriguing Relationship
Abstract
Sarcoidosis is a systemic granulomatous disorder of unknown etiology, most commonly affecting the lungs but potentially involving multiple organs. Fatigue and Excessive Daytime Sleepiness (EDS) represent highly prevalent and disabling symptoms, often persisting despite stable systemic disease. Growing evidence indicates an increased prevalence of Obstructive Sleep Apnoea (OSA) among patients with sarcoidosis, suggesting a complex and multifactorial association. Several mechanisms contribute to this link. Shared inflammatory pathways promote systemic inflammation and vascular dysfunction. Corticosteroid therapy, although central to sarcoidosis management, indirectly predisposes to OSA through weight gain, fat redistribution, and myopathy. Direct upper airway involvement (sarcoidosis of the upper respiratory tract, SURT) may cause mechanical obstruction, while restrictive pulmonary disease reduces lung volumes and increases pharyngeal collapsibility. Clinical studies consistently report a higher prevalence of OSA in sarcoidosis compared with the general population, even in non-obese and treatment-naïve patients. While OSA contributes to fatigue and EDS, these symptoms are also influenced by immune dysregulation, chronic inflammation, and treatment side effects. Continuous Positive Airway Pressure (CPAP) therapy has demonstrated efficacy in reducing apnoea burden and improving both fatigue and quality of life, underscoring the importance of systematic OSA screening in…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.